Skip to Main Content

Paper Details

Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.
Blood Adv
1
2023
Author NameAffiliation
Andrew M EvensRutgers Cancer Institute of New Jersey
Francisco VegaUniversity of Texas MD Anderson Cancer Center
  • 1 - 2

Datasets

Release 1.2